These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38305302)

  • 21. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
    Lee YH; Bae SC
    Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses.
    Pantavou K; Yiallourou AI; Piovani D; Evripidou D; Danese S; Peyrin-Biroulet L; Bonovas S; Nikolopoulos GK
    United European Gastroenterol J; 2019 Dec; 7(10):1285-1303. PubMed ID: 31839954
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
    Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
    Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tofacitinib Salvage Therapy for Children Hospitalized for Corticosteroid- and Biologic-Refractory Ulcerative Colitis.
    Constant BD; Baldassano R; Kirsch J; Mitchel EB; Stein R; Albenberg L
    J Pediatr Gastroenterol Nutr; 2022 Dec; 75(6):724-730. PubMed ID: 36122389
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Higher Surgical Morbidity for Ulcerative Colitis Patients in the Era of Biologics.
    Abelson JS; Michelassi F; Mao J; Sedrakyan A; Yeo H
    Ann Surg; 2018 Aug; 268(2):311-317. PubMed ID: 28448381
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of biologic and small molecule agents as second-line therapy after exposure to TNF inhibitors in patients with ulcerative colitis: A propensity-matched cohort study.
    Kochhar GS; Desai A; Farraye FA; Cross RK; El-Hachem S; Dulai PS; Regueiro M
    Aliment Pharmacol Ther; 2023 Aug; 58(3):297-308. PubMed ID: 37300328
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Systematic review with network meta-analysis: comparative assessment of tofacitinib and biological therapies for moderate-to-severe ulcerative colitis.
    Bonovas S; Lytras T; Nikolopoulos G; Peyrin-Biroulet L; Danese S
    Aliment Pharmacol Ther; 2018 Feb; 47(4):454-465. PubMed ID: 29205421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Operative strategy modifies risk of pouch-related outcomes in patients with ulcerative colitis on preoperative anti-tumor necrosis factor-α therapy.
    Gu J; Remzi FH; Shen B; Vogel JD; Kiran RP
    Dis Colon Rectum; 2013 Nov; 56(11):1243-52. PubMed ID: 24104999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surgical Outcomes in Vedolizumab-Treated Patients with Ulcerative Colitis.
    Lightner AL; McKenna NP; Moncrief S; Pemberton JH; Raffals LE; Mathis KL
    Inflamm Bowel Dis; 2017 Dec; 23(12):2197-2201. PubMed ID: 28858072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pre-operative use of anti-TNF-α agents and the risk of post-operative complications in patients with ulcerative colitis - a nationwide cohort study.
    Nørgård BM; Nielsen J; Qvist N; Gradel KO; de Muckadell OB; Kjeldsen J
    Aliment Pharmacol Ther; 2012 Jun; 35(11):1301-9. PubMed ID: 22506582
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tofacitinib Exposure Does Not Increase Postoperative Complications Among Patients With Ulcerative Colitis Undergoing Total Colectomy: A Retrospective Case-Control Study.
    Gomaa I; Aboelmaaty S; Bhatt H; Vierkant RA; Shawki SF; Larson DW; Behm KT; Rumer KK
    Dis Colon Rectum; 2024 Nov; 67(11):1443-1449. PubMed ID: 39087684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world efficacy and safety of tofacitinib treatment in Asian patients with ulcerative colitis.
    Kojima K; Watanabe K; Kawai M; Yagi S; Kaku K; Ikenouchi M; Sato T; Kamikozuru K; Yokoyama Y; Takagawa T; Shimizu M; Shinzaki S
    World J Gastroenterol; 2024 Apr; 30(13):1871-1886. PubMed ID: 38659488
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of tofacitinib compared with infliximab, adalimumab, golimumab, vedolizumab and ustekinumab for the treatment of moderate to severe ulcerative colitis in Germany.
    Sardesai A; Dignass A; Quon P; Milev S; Cappelleri JC; Kisser A; Modesto I; Sharma PP
    J Med Econ; 2021; 24(1):279-290. PubMed ID: 33502905
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An economic evaluation of tofacitinib for the treatment of moderately-to-severely active ulcerative colitis: modeling the cost of treatment strategies in the United States.
    Milev S; DiBonaventura MD; Quon P; Wern Goh J; Bourret J; Peeples-Lamirande K; Soonasra A; Cappelleri JC; Quirk D
    J Med Econ; 2019 Sep; 22(9):859-868. PubMed ID: 31012362
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis.
    Zhou HY; Guo B; Lufumpa E; Li XM; Chen LH; Meng X; Li BZ
    Immunol Invest; 2021 May; 50(4):323-337. PubMed ID: 32009472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control Study.
    Berinstein JA; Sheehan JL; Dias M; Berinstein EM; Steiner CA; Johnson LA; Regal RE; Allen JI; Cushing KC; Stidham RW; Bishu S; Kinnucan JAR; Cohen-Mekelburg SA; Waljee AK; Higgins PDR
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2112-2120.e1. PubMed ID: 34048936
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
    Shaffer SR; Huang E; Patel S; Rubin DT
    Am J Gastroenterol; 2021 Jan; 116(1):125-133. PubMed ID: 32947317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgery for Ulcerative Colitis Is Associated with a High Rate of Readmissions at 30 Days.
    Feuerstein JD; Jiang ZG; Belkin E; Lewandowski JJ; Martinez-Vazquez M; Singla A; Cataldo T; Poylin V; Cheifetz AS
    Inflamm Bowel Dis; 2015 Sep; 21(9):2130-6. PubMed ID: 26020605
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.
    Singh JA; Hossain A; Mudano AS; Tanjong Ghogomu E; Suarez-Almazor ME; Buchbinder R; Maxwell LJ; Tugwell P; Wells GA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD012657. PubMed ID: 28481462
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Integrating efficacy and safety of vedolizumab compared with other advanced therapies to assess net clinical benefit of ulcerative colitis treatments: a network meta-analysis.
    Jairath V; Chan K; Lasch K; Keeping S; Agboton C; Blake A; Patel H
    Expert Rev Gastroenterol Hepatol; 2021 Jun; 15(6):711-722. PubMed ID: 33599181
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.